Shenzhen Business Daily · Reading Client Reporter Liang Jiatong
On the evening of October 14, Bio-Thera (688177) announced that due to the withdrawal of investment projects and the need for capital arrangements, Dongtai Qiheng plans to reduce its holdings of the company's shares through centralized bidding and block trading, with a total of no more than 8.2816 million shares, accounting for no more than 2% of the company's total share capital.
Among them, no more than 4,140,800 shares (including the number of shares) were reduced through centralized bidding transactions, accounting for no more than 1% of the company's total share capital; The reduction of shares through block trading shall not exceed 4,140,800 shares (including the number of shares), accounting for no more than 1% of the company's total share capital.
As of the disclosure date of this announcement, Dongtai Qiheng and its concerted actor Hui Tianze held a total of 24,552,770 shares of the company, accounting for 5.93% of the company's total share capital, of which the number of outstanding shares was 24,552,770 shares, accounting for 5.93% of the company's total share capital. According to the Tianyancha APP, Dongtai Qiheng is the fifth largest shareholder of Bio-Thee.
The reporter noticed that the shareholders of Bio-Thera have been reducing their holdings in recent years.
On June 4, Therabio, a shareholder of more than 5% of the company, and its concerted actors returned to Wanhu to reduce their holdings of the company's shares through block trading, with a total number of no more than 2% of the company's total share capital. However, on September 4, Bio-Thera disclosed that the above-mentioned shareholder shareholding reduction plan had not been reduced by the expiration of the time.
On March 1, the company received the "Notification Letter on the Expiration of the Shareholding Reduction Plan and the Result of the Shareholding Reduction" issued by shareholders Dongtai Qiheng (formerly Jifu Qiheng), Hefei Qixing and Hui Tianze, Dongtai Qiheng (formerly Jifu Qiheng), Hefei Qixing and Huitianze reduced their holdings of 4,284,436 shares of the company through centralized bidding in this shareholding reduction plan, accounting for 1.03% of the company's total shares.
On July 11, 2023, the company received the "Notification Letter on the Expiration of the Shareholding Reduction Plan and the Result of the Shareholding Reduction" issued by shareholders Jifu Qiheng, Hui Tianze, Hefei Qixing and Hui Zhifu, Hefei Qixing and Hui Zhifu reduced their holdings of 3,809,012 shares of the company through centralized bidding transactions in this shareholding reduction plan, accounting for 0.92% of the company's total shares.
According to public information, the main business of Bio-Thera Biopharmaceutical Co., Ltd. is the research and development, production and sales of drugs. The company's main products are innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life or health.
In terms of finance, Bio-Thera achieved a total operating income of 402 million yuan in the first half of 2024, a year-on-year increase of 27.85%; The net profit loss attributable to the parent company was 237 million yuan, compared with a loss of 254 million yuan in the same period last year, the loss of non-net profit was 270 million yuan, a loss of 286 million yuan in the same period last year, and the net cash flow from operating activities was -63.2601 million yuan, compared with -219 million yuan in the same period last year.
Looking back on the performance of previous years, Bio-Thera has only achieved profitability in 2021 in the past five years. From 2019 to 2023, the company's net profit attributable to the parent company will be -1.023 billion yuan, -513 million yuan, 82 million yuan, -480 million yuan and -395 million yuan respectively, with a cumulative loss of more than 2.3 billion yuan in five years.
In the secondary market, as of the close of trading on the 14th, Bio-Thera closed down 0.13% at 23.31 yuan per share, with the latest market value of 9.652 billion yuan, down 43% this year.